Tumor-Antigen-Specific Memory CD8 T Cell Amplification for PD-1 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy strategies, such as PD-1 immune checkpoint blockade, have limited efficacy and face challenges in overcoming CD8 T cell exhaustion, particularly due to the low proportion and limited proliferative potential of progenitor exhausted T cells infiltrating tumor tissues, necessitating the identification of new key CD8 T cell subsets that respond to therapy.
Innovation Solution
Identification and amplification of a novel subset of tumor antigen-specific memory CD8 T cells in draining lymph nodes, characterized by high expression of CD62L, CD127, CD122, and CCR7, and low expression of inhibitory receptors, which are essential for continuous replenishment and maintenance of exhausted CD8 T cells, and can synergize with PD-1/PD-L1 immune checkpoint blockade therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 immune checkpoint blockade therapy is used, then the anti-tumor immune response is enhanced, but the overall patient response rate remains low at about 30%
Solution Approach 1:
The patent segments the CD8 T cell population into distinct functional subsets (exhausted T cells, memory T cells, effector T cells) based on their molecular markers and functional states. This segmentation reveals that memory CD8 T cells, rather than exhausted T cells, are the key responders to PD-1 blockade therapy, thereby resolving the contradiction by identifying the correct target population that drives therapeutic efficacy.
Solution Approach 2:
The patent inverts the conventional understanding by demonstrating that memory CD8 T cells (not exhausted T cells) are the critical population responding to PD-1 blockade. This inversion of the expected cell type explanation resolves the contradiction by providing a new mechanistic understanding that aligns with the observed 30% response rate while identifying potential strategies to expand this responsive population.
2Reliability
If progenitor exhausted T cells infiltrating tumor tissues are targeted, then PD-1 immune checkpoint therapy response is explained, but the low proportion and limited proliferative potential of these cells makes it difficult to explain the significant anti-tumor effect
Solution Approach 1:
The patent inverts the conventional attribution by showing that memory CD8 T cells, not progenitor exhausted T cells, are the primary drivers of PD-1 blockade response. This inversion resolves the quantitative contradiction by identifying a cell population with superior proliferative potential that can account for the significant anti-tumor effects observed clinically.
Solution Approach 2:
The patent introduces memory CD8 T cells as an intermediary population that bridges the gap between initial antigen exposure and sustained anti-tumor immunity. These memory cells serve as a mediator that can be activated by PD-1 blockade and subsequently proliferate to generate effector responses, thereby explaining the significant anti-tumor effects without relying on the limited progenitor exhausted T cell population.
3Reliability
If exhausted CD8 T cells are present in tumor tissues, then immune surveillance function is established, but they gradually lose their function of cytokine secretion and cytotoxicity due to continuous stimulation by immunosuppressive molecules
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing memory CD8 T cells that exist in a pre-activated state within the tumor microenvironment before exhaustive dysfunction sets in. These memory cells represent an intermediate state that has not yet lost its functional potential, allowing for intervention before complete exhaustion occurs.
Solution Approach 2:
The patent applies dynamics by demonstrating the dynamic transition of CD8 T cells from memory to exhausted states through continuous antigen stimulation and immunosuppressive signaling. By identifying the memory population as a distinct dynamic state, the patent reveals a window of opportunity for therapeutic intervention that can prevent or reverse functional loss.
Data Source
Figure 1A~1B
Figure 2
Figure 3A~4D
AI summary
The present application provides identification, in vitro amplification, and application method of memory CD8 T cells specific for an antigen in a solid tumor-draining lymph node.